Abstract: A method of preparing a variola virus which comprises growing the virus on the embryos of chicken eggs, recoverng the inoculated embryos, stabilizing the recovered embryos with a mixture comprising; lactose, raffinose, lysine, sodium glutamate, dextrin, isoniazid and thiourea.

Abstract: A method of coating a dry variola virus obtained by the inoculation of the mbryo of chicken eggs and stabilized by the addition of lactose, raffinose, lysine, sodium glutamate, isoniazid, and thiourea by treatment with methyl amyl acetate.

Abstract: A method for enhancing the production of interferon from normal human diploid fibroblast cells is disclosed. In this method, a distinct interferon-production phase is established in which the temperature is initially elevated for a brief period followed by a reduction in temperature for the balance of the interferon-production phase.

Abstract: A human osteogenic sarcoma cell line chronically infected with human cytomegalovirus having a substantially constant ratio between immunofluorescent positive and noninfected cells useful in the immunofluorescent serological test for determining the presence of human cytomegalovirus antibody.

Abstract: A process for producing an insulin-producing conditionally transformed pancreatic cell line is provided. The process of the present invention comprises the steps of preparing and culturing a population of insulin-producing pancreatic beta cells, preparing and culturing a suitable strain of Rous sarcoma virus containing a temperature sensitive lesion in the viral transforming or sarc gene, and infecting the insulin-producing pancreatic cells with the temperature sensitive virus. The infected pancreatic cells are conditionally transformed by the temperature-sensitive virus to provide an insulin-producing system especially suited for both in vitro and in vivo application. Methods for evaluating the safety of the system for application in vivo are also disclosed.

Abstract: Double-stranded RNA synthesized using native human DNA as template is found to be an excellent interferon inducer with low toxicity in spite of homologous native to host cell. It is produced by reacting ATP, GTP, CTP and UTP with one another in the presence of a native human DNA as template by the catalytic action of an active RNA polymerase to form RNA and subjecting the resulting RNA to annealing by heating it at a temperature of 70.degree. to 100.degree. C. and gradually cooling to room temperature or below to form double-stranded regions between their molecules.

Abstract: Described herein is a method for the extraction of an active biochemical factor that restores contact inhibition of growth to malignant cell types of different mammalian species.

Abstract: A method for preparing interferon in which MRC-5 cells are induced for 2 to 3 hours with an interferon-inducing medium containing from 0.1 to 50 mg 1.sup.-1 of a ds-RNA, 100 mg 1.sup.-1 of DEAE-Dextran and 250 m.M of sucrose.Other sugars which can be used include glucose, galactose, fructose, mannose and maltose, and a preferred ds-RNA is naturally occurring ds-RNA isolated from P. chrysogenum.

Abstract: A new system of serially culturing anterior pituitary gland cells in a new nutrient medium under open aeration to produce large amounts of pituitary hormones. Using the new system of culture and new nutrient media, the pituitary cells can be grown in vitro to produce in approximately three weeks 10 to 12 times the amount of extractable hormone originally present in the original tissue.

Abstract: Process for the production of human angiogenic factor in vitro comprising growing cells of human foreskin fibroblast cell line on support surface in nutrient culture medium at about 35.degree.-38.degree. C. for a sufficient time to elaborate angiogenic factor and recovering the resulting angiogenic factor from the cells or cell product.

Abstract: Cell lines for producing monoclonal antibodies to hepatitis virus are established by immunizing animal lymphocytes with hepatitis antigen to form antibody producing cells which then are fused with myeloma cells. The resultant somatic cell hybrids can be cloned. These clones produce monoclonal antibodies to individual antigenic determinates unique to hepatitis virus.

Abstract: Process for the production of human angiogenic factor in vitro comprising growing the human diploid cell line IMR-90 on support surface in nutrient culture medium at about 35.degree.-38.degree. C. for a sufficient time to elaborate angiogenic factor and recovering the resulting angiogenic factor from the cells or cell product.

Abstract: Process for the production of human TAF in vitro comprising growing the human colon adenocarcinoma cell line HT-29 in agitated, liquid suspension of nutrient culture medium at about 35.degree.-38.degree. C. for a sufficient time to elaborate TAF and recovering the resulting TAF from the cells or cell product.

Abstract: Process for the production of human TAF in vitro comprising growing the human osteosarcoma cell line MG-63 in agitated, liquid suspension of nutrient culture medium at about 35.degree.-38.degree. C. for a sufficient time to elaborate TAF and recovering the resulting TAF from the cells or cell product.

Abstract: Process for the production of human TAF in vitro comprising growing the human Burkitt lymphoma cell line Raji in agitated, liquid suspension of nutrient culture medium at about 35.degree.-38.degree. C. for a sufficient time to elaborate TAF and recovering the resulting TAF from the cells or cell product.

Abstract: Process for the production of human TAF in vitro comprising growing the human medulloblastoma cell line TE-671 in agitated, liquid suspension of nutrient culture medium at about 35.degree.-38.degree. C. for a sufficient time to elaborate TAF and recovering the resulting TAF from the cells or cell product.

Abstract: Process for the production of human TAF in vitro comprising growing the human melanoma cell line A-375 in agitated, liquid suspension of nutrient culture medium at about 35.degree.-38.degree. C. for a sufficient time to elaborate TAF and recovering the resulting TAF from the cells or cell product.

Abstract: Process for the production of human TAF in vitro comprising growing the human rhabdomyosarcoma cell line RD in agitated, liquid suspension of nutrient culture medium at about 35.degree.-38.degree. C. for a sufficient time to elaborate TAF and recovering the resulting TAF from the cells or cell product.

Abstract: Process for the production of human TAF in vitro comprising growing the human liver adenocardinoma cell line SK-HEP-1 in agitated, liquid suspension of nutrient culture medium at about 35.degree.-38.degree. C. for a sufficient time to elaborate TAF and recovering the resulting TAF from the cells or cell product.